AOD-9604
A synthetic fragment of human growth hormone investigated for metabolic effects, with limited human evidence.
On this page
WHAT THE EVIDENCE SAYS
AOD-9604 evidence summary.
AOD-9604 is a useful example of why preclinical promise is not enough: substantial human development did not produce persuasive efficacy or an approved obesity indication.
01 / CLASSIFICATION
What is AOD-9604?
Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.
02 / EVIDENCE
AOD-9604 human and preclinical evidence.
The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.
03 / STATUS
AOD-9604 FDA and sport status.
Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.
04 / RESEARCH AREAS
What is AOD-9604 being studied for?
05 / COMPARISONS
Compare AOD-9604.
06 / LATEST & DEFINING SOURCES
AOD-9604 primary and official sources.
07 / QUESTIONS
Questions about AOD-9604.
Start with identity, research, human evidence, approval, sport status, and the limits of the current record.
AOD-9604 is a useful example of why preclinical promise is not enough: substantial human development did not produce persuasive efficacy or an approved obesity indication.
Current source-backed research areas include Obesity, Lipolysis, Growth hormone fragments, Cartilage research. These areas describe investigation, not established personal benefit.
Current U.S. status for AOD-9604: No FDA-approved AOD-9604 drug product; FDA identifies limited safety information and potential concerns for compounded use.
Current sport-status snapshot for AOD-9604: Prohibited at all times under the 2026 WADA List (S2) as a growth-hormone fragment.
The existence of a large trial should not be summarized as positive evidence when the development result was not clinically persuasive.